Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

ANNX

Annexon Inc

Feb 21 • 04:00PM ET

2.81

Dollar change -0.02
Percentage change -0.71	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX RARE CRSP NTLA EDIT ALLO BLUE FOLD MYO SGMO

| Held by: VTI IWM XBI VXF IWN VTWO IBB SCHA VHT DFAC

Index	RUT	P/E	-	EPS (ttm)	-1.04	Insider Own	13.12%	Shs Outstand	105.71M	Perf Week	-6.64%
Market Cap	299.53M	Forward P/E	-	EPS next Y	-1.08	Insider Trans	-0.43%	Shs Float	92.61M	Perf Month	-32.29%
Income	-117.50M	PEG	-	EPS next Q	-0.27	Inst Own	93.63%	Short Float	10.89%	Perf Quarter	-48.53%
Sales	0.00M	P/S	-	EPS this Y	46.05%	Inst Trans	2.64%	Short Ratio	7.11	Perf Half Y	-53.09%
Book/sh	3.14	P/B	0.90	EPS next Y	-13.42%	ROA	-40.34%	Short Interest	10.09M	Perf Year	-45.86%
Cash/sh	3.19	P/C	0.88	EPS next 5Y	17.54%	ROE	-48.12%	52W Range	2.63 - 8.40	Perf YTD	-45.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-29.69%	ROI	-32.75%	52W High	-66.55%	Beta	1.07
Dividend TTM	-	Quick Ratio	17.18	Sales past 5Y	0.00%	Gross Margin	-	52W Low	6.64%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	17.18	EPS Y/Y TTM	45.29%	Oper. Margin	-	RSI (14)	26.19	Volatility	8.86% 7.67%
Employees	71	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	15.17
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	42.26%	Payout	-	Rel Volume	0.41	Prev Close	2.83
Sales Surprise	-	EPS Surprise	3.18%	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	1.42M	Price	2.81
SMA20	-18.31%	SMA50	-34.43%	SMA200	-48.90%	Trades		Volume	578,088	Change	-0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight	$11
Dec-21-23	Upgrade	BofA Securities	Neutral → Buy	$4 → $6
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Feb-18-25 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.05%
Feb-13-25 08:30AM	Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting (GlobeNewswire)
Jan-13-25 08:00AM	Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year (GlobeNewswire)
Jan-10-25 08:00AM	Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones (GlobeNewswire)
Jan-07-25 08:00AM	Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
04:05PM	Loading…
Dec-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.96%
07:30AM	Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Dec-05-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting (GlobeNewswire)
Nov-19-24 03:00AM	The Dodgers World Series run brought attention to a rare disease. Annexon is stepping up to the plate. (Pharma Voice)
Nov-15-24 04:59PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.78%
Nov-14-24 08:00AM	Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Nov-13-24 04:05PM	Annexon Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 08:00PM	Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Oct-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 08:00AM	Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
08:00AM	Loading…
Sep-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress (GlobeNewswire) +8.17%
Sep-03-24 08:00AM	Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio (GlobeNewswire) -5.09%
Aug-29-24 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 08:00AM	Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Aug-05-24 08:00AM	Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy (GlobeNewswire) -9.38%
Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
08:00AM	Loading…
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 11:04PM	Annexon Announces Pricing of $125 Million Underwritten Public Offering (GlobeNewswire) +13.36% -13.25%
10:57AM	Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals (Zacks)
09:55AM	Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet (Zacks)
04:45AM	Annexons ANX005 offers improvement in Phase III GBS trial (Clinical Trials Arena)
Jun-04-24 05:06PM	Annexon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +30.79%
12:06PM	Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study (Benzinga)
08:46AM	Annexon shares leap as Guillain-Barr drug reduces disability in phase 3 (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barre Syndrome (GlobeNewswire)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barr Syndrome (GlobeNewswire)
Jun-03-24 04:30PM	Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data (GlobeNewswire) -5.18%
May-20-24 09:35AM	Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.08%
May-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 02:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones (GlobeNewswire)
May-09-24 08:00AM	Annexon Biosciences to Present at the Bank of America Health Care Conference (GlobeNewswire)
May-07-24 12:30PM	Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting (GlobeNewswire)
May-01-24 10:15AM	Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? (Zacks)
08:00AM	Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-25-24 09:35AM	Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX) (Zacks)
Apr-17-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks) -10.36%
Apr-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.89%
09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-10-24 06:15PM	Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Apr-03-24 08:00AM	Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 12:00PM	What Makes Annexon (ANNX) a New Buy Stock (Zacks) -7.53%
09:55AM	Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade (Zacks)
Mar-28-24 05:31AM	Annexon Inc (ANNX) Reports Year-End Financials, Aligns with Analyst Projections (GuruFocus.com) -8.19%
Mar-26-24 08:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q4 2023 (InvestorPlace) +13.52%
04:05PM	Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones (GlobeNewswire)
Mar-18-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.98%
Mar-14-24 08:40AM	Why Annexon (ANNX) Might Surprise This Earnings Season (Zacks)
Mar-12-24 02:51PM	J.P. Morgan Predicts up to 140% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-24 08:00AM	Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-21-24 08:00AM	Annexon to Host Virtual R&D Day on Guillain-Barr Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach (GlobeNewswire) -5.39%
Feb-20-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-13-24 01:10PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Annexon Inc (GuruFocus.com) -7.73%
Jan-18-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.87%
Jan-17-24 11:06AM	Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How (Zacks)
Jan-07-24 08:00PM	Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases (GlobeNewswire)
Dec-27-23 06:30AM	Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 05:27PM	Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +29.51%
05:10PM	Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint (GlobeNewswire)
05:08PM	Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway (GlobeNewswire)
Dec-18-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-23 04:01PM	Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +8.37%
Nov-14-23 07:20PM	Annexon Inc (ANNX) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com) +9.73%
Nov-13-23 06:30AM	Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results (GlobeNewswire) +6.35%
Nov-09-23 06:30AM	Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference (GlobeNewswire)
Oct-24-23 06:30AM	Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy (GlobeNewswire) +8.33%
Oct-18-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-10-23 06:30AM	Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Sep-19-23 06:30AM	Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-18-23 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-23 09:35AM	Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX) (Zacks)
Aug-07-23 06:30AM	Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-02-23 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-30-23 12:00PM	Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy (GlobeNewswire)
Jul-27-23 06:30AM	Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer (GlobeNewswire) -6.82%
Jul-24-23 06:30AM	Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023 (GlobeNewswire)
Jun-14-23 08:36AM	Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation (Simply Wall St.) -5.48%
May-30-23 10:40AM	Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why (Zacks)
May-26-23 03:05AM	4 big analyst cuts: Snowflake downgraded twice on guidance miss (Investing.com) +35.71%
May-25-23 11:52AM	Why Shares of Annexon Are Plummeting Thursday (Motley Fool) -59.38%
10:12AM	Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study (Benzinga)
May-24-23 04:01PM	Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function (GlobeNewswire) -7.84%

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dananberg Jamie	CHIEF MEDICAL OFFICER	Feb 18 '25	Sale	2.96	5,521	16,342	33,479	Feb 20 04:54 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	2.97	5,515	16,380	83,814	Feb 20 04:52 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 18 '25	Sale	2.91	8,345	24,284	61,237	Feb 20 04:51 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 18 '25	Sale	2.95	6,618	19,523	86,579	Feb 20 04:49 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 18 '25	Sale	2.92	6,912	20,183	77,770	Feb 20 04:48 PM
Love Douglas	PRESIDENT AND CEO	Feb 13 '25	Sale	2.95	5,021	14,812	351,554	Feb 18 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 13 '25	Sale	2.98	1,786	5,322	84,682	Feb 18 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 13 '25	Sale	2.99	1,425	4,261	93,197	Feb 18 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 13 '25	Sale	2.99	1,783	5,331	69,582	Feb 18 04:30 PM
Yednock Ted	Officer	Feb 18 '25	Proposed Sale	2.91	8,345	24,321		Feb 18 03:21 PM
Lew Jennifer	Officer	Feb 18 '25	Proposed Sale	2.92	8,338	24,319		Feb 18 03:15 PM
ARTIS DEAN RICHARD	Officer	Feb 18 '25	Proposed Sale	2.97	5,515	16,359		Feb 18 03:15 PM
Dananberg Jamie	Officer	Feb 18 '25	Proposed Sale	2.96	5,521	16,359		Feb 18 03:13 PM
Overdorf Michael	Officer	Feb 18 '25	Proposed Sale	2.95	6,618	19,514		Feb 18 03:11 PM
Yednock Ted	Officer	Feb 13 '25	Proposed Sale	2.98	1,783	5,316		Feb 13 03:18 PM
Love Douglas	Officer	Feb 13 '25	Proposed Sale	2.95	5,021	14,799		Feb 13 03:13 PM
Lew Jennifer	Officer	Feb 13 '25	Proposed Sale	2.98	1,786	5,314		Feb 13 03:12 PM
Overdorf Michael	Officer	Feb 13 '25	Proposed Sale	2.99	1,425	4,265		Feb 13 03:06 PM
Love Douglas	PRESIDENT AND CEO	Jan 06 '25	Option Exercise	1.41	37,994	53,556	356,575	Jan 08 05:58 PM
Carson William H.	Director	Dec 02 '24	Buy	5.33	3,200	17,056	25,600	Dec 04 06:12 PM
Love Douglas	PRESIDENT AND CEO	Oct 30 '24	Option Exercise	1.85	114,449	211,742	310,570	Nov 01 04:15 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Oct 15 '24	Option Exercise	1.85	5,408	10,005	76,773	Oct 17 05:09 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Oct 15 '24	Sale	7.41	5,408	40,073	71,365	Oct 17 05:09 PM
Yednock Ted	Officer	Oct 15 '24	Proposed Sale	7.41	5,408	40,073		Oct 15 02:03 PM
Carson William H.	Director	Oct 01 '24	Buy	5.97	3,200	19,104	22,400	Oct 02 04:15 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 19 '24	Sale	7.10	4,500	31,950	0	Sep 20 04:30 PM
Yednock Ted	Officer	Sep 19 '24	Proposed Sale	7.10	4,500	31,950		Sep 19 12:32 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 12 '24	Sale	6.16	5,500	33,880	4,500	Sep 16 04:30 PM
Yednock Ted	Officer	Sep 12 '24	Proposed Sale	6.16	5,500	33,880		Sep 12 10:24 AM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 05 '24	Sale	5.64	5,500	31,020	10,000	Sep 06 04:30 PM
Yednock Ted	Officer	Sep 05 '24	Proposed Sale	5.64	5,500	31,020		Sep 05 10:15 AM
Carson William H.	Director	Sep 03 '24	Buy	5.48	3,200	17,536	19,200	Sep 04 04:34 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Aug 29 '24	Sale	5.95	5,500	32,725	15,500	Aug 30 06:00 PM
Yednock Ted	Officer	Aug 29 '24	Proposed Sale	5.95	5,500	32,725		Aug 29 02:08 PM
Carson William H.	Director	Aug 01 '24	Buy	6.24	3,200	19,968	16,000	Aug 05 07:53 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Jul 15 '24	Sale	6.02	784	4,720	94,622	Jul 17 04:49 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Jul 15 '24	Sale	6.03	1,104	6,657	86,468	Jul 17 04:48 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jul 15 '24	Sale	6.02	1,106	6,658	71,365	Jul 17 04:46 PM
Carson William H.	Director	Jul 01 '24	Buy	5.00	3,200	16,000	12,800	Jul 02 05:43 PM
Carson William H.	Director	Jun 03 '24	Buy	4.83	3,200	15,459	9,600	Jun 05 04:23 PM
Carson William H.	Director	May 01 '24	Buy	4.68	3,200	14,982	6,400	May 03 04:15 PM
Carson William H.	Director	Apr 08 '24	Buy	6.07	3,200	19,411	3,200	Apr 10 07:17 PM

Dollar change -0.11
Percentage change -5.37	%

UBX Unity Biotechnology Inc daily Stock Chart

Peers: FATE ALDX FBIO ANVS PBYI CRVS DRRX CYCN CALM SPRO

| Held by: VTI VXF DFAS

Index	-	P/E	-	EPS (ttm)	-1.32	Insider Own	8.79%	Shs Outstand	16.85M	Perf Week	-2.02%
Market Cap	32.69M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	-0.11%	Shs Float	15.37M	Perf Month	-7.18%
Income	-21.89M	PEG	-	EPS next Q	-0.39	Inst Own	12.54%	Short Float	3.00%	Perf Quarter	63.03%
Sales	0.00M	P/S	-	EPS this Y	49.22%	Inst Trans	-7.57%	Short Ratio	1.92	Perf Half Y	28.48%
Book/sh	0.84	P/B	2.31	EPS next Y	26.37%	ROA	-37.61%	Short Interest	0.46M	Perf Year	6.01%
Cash/sh	1.72	P/C	1.13	EPS next 5Y	29.27%	ROE	-86.95%	52W Range	0.94 - 3.10	Perf YTD	98.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.93%	ROI	-62.82%	52W High	-37.42%	Beta	0.99
Dividend TTM	-	Quick Ratio	3.45	Sales past 5Y	-48.77%	Gross Margin	-	52W Low	106.45%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	3.45	EPS Y/Y TTM	63.90%	Oper. Margin	-	RSI (14)	48.69	Volatility	10.82% 13.74%
Employees	19	Debt/Eq	1.73	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	6.50
Option/Short	Yes / Yes	LT Debt/Eq	1.46	EPS Q/Q	63.28%	Payout	-	Rel Volume	0.41	Prev Close	2.05
Sales Surprise	-	EPS Surprise	5.85%	Sales Q/Q	-	Earnings	Nov 04 AMC	Avg Volume	240.16K	Price	1.94
SMA20	-9.19%	SMA50	16.05%	SMA200	30.40%	Trades		Volume	98,813	Change	-5.37%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-22-24	Initiated	Rodman & Renshaw	Buy	$8
Nov-16-23	Upgrade	Wedbush	Neutral → Outperform	$2 → $4
Jan-04-22	Upgrade	ROTH Capital	Neutral → Buy
Nov-10-21	Upgrade	Mizuho	Neutral → Buy	$5 → $7
Jun-28-21	Upgrade	Citigroup	Sell → Buy	$6
Jun-07-21	Initiated	H.C. Wainwright	Buy	$12
Feb-16-21	Downgrade	Citigroup	Neutral → Sell	$5 → $6
Aug-18-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$5
Aug-18-20	Downgrade	Mizuho	Buy → Neutral	$33 → $4
Aug-18-20	Downgrade	Citigroup	Buy → Neutral	$31 → $5
Aug-17-20	Downgrade	ROTH Capital	Buy → Neutral
Jul-28-20	Initiated	ROTH Capital	Buy	$35
Dec-12-19	Initiated	Cantor Fitzgerald	Overweight	$20
Mar-07-19	Initiated	Cantor Fitzgerald	Overweight	$21
Sep-07-18	Initiated	Mizuho	Buy
May-29-18	Initiated	Morgan Stanley	Overweight	$25
May-29-18	Initiated	Goldman	Neutral	$17
May-29-18	Initiated	Citigroup	Buy	$32

Show Previous Ratings

Jan-07-25 04:10PM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire) -26.52%
Jan-06-25 08:00AM	UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) +39.06%
Nov-04-24 04:30PM	UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Sep-24-24 08:00AM	UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 (GlobeNewswire)
Aug-12-24 08:00AM	UNITY Biotechnology to Participate in Upcoming Investor Conferences (GlobeNewswire)
12:00PM	Loading…
Aug-09-24 12:00PM	UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-06-24 04:30PM	UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Jul-24-24 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire)
Jul-22-24 08:00AM	UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer (GlobeNewswire)
May-17-24 12:00PM	All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy (Zacks)
May-14-24 10:53PM	UBX Stock Earnings: Unity Biotechnology Beats EPS for Q1 2024 (InvestorPlace)
05:00PM	UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Apr-25-24 08:00AM	UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-23-24 10:37AM	Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment (MT Newswires)
08:00AM	UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME (GlobeNewswire)
11:52AM	Loading…
Apr-15-24 11:52AM	UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
Feb-06-24 08:00AM	New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss (GlobeNewswire)
Dec-29-23 04:37PM	10 Supplements for Longevity and Antiaging: Expert Recommendations (Insider Monkey)
Dec-12-23 08:00AM	UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME (GlobeNewswire)
Nov-13-23 04:05PM	UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Nov-10-23 08:00AM	UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds (GlobeNewswire) -6.25%
Oct-17-23 05:14PM	Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks (InvestorPlace) +17.86% -12.82%
Oct-03-23 09:36PM	20 Foods Consumed By Longest Living People Every Day (Insider Monkey) -6.06%
Sep-27-23 07:00AM	UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration (GlobeNewswire)
Sep-16-23 01:02AM	Unity Biotechnology Inc CEO Anirvan Ghosh Sells 1,246 Shares (GuruFocus.com)
Aug-15-23 04:51PM	20 States With The Longest Life Expectancy In America (Insider Monkey)
Aug-08-23 04:05PM	UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jun-21-23 07:00AM	UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME) (GlobeNewswire)
May-09-23 04:05PM	UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire) +15.66%
01:34PM	Loading…
Apr-24-23 01:34PM	Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea (Benzinga) -5.19%
07:00AM	UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema (GlobeNewswire)
Apr-23-23 06:00PM	UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema (GlobeNewswire)
Mar-28-23 03:25PM	Unity (UNX) Down on Disappointing Results From Wet AMD Study (Zacks) -10.26%
Mar-27-23 01:28PM	UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug (Benzinga) -53.01%
07:30AM	UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration (GlobeNewswire)
Mar-15-23 04:05PM	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Feb-28-23 04:05PM	UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-15-23 08:00AM	UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire) +10.74%
Feb-09-23 08:00AM	UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study (GlobeNewswire)
Jan-18-23 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire) +7.32%
Jan-10-23 10:36AM	10 Penny Stocks That Will Make You A Millionaire (Insider Monkey) +9.48%
Nov-08-22 04:10PM	UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -14.02%
Nov-01-22 07:00AM	UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema (GlobeNewswire)
Oct-31-22 06:11PM	UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema (GlobeNewswire) +12.60%
Oct-19-22 08:30AM	UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today (GlobeNewswire) -14.49%
Oct-11-22 08:00AM	UNITY Biotechnologys Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye (GlobeNewswire) -5.34%
Oct-10-22 12:00PM	All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy (Zacks)
Oct-06-22 08:00AM	UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye (GlobeNewswire)
Sep-19-22 08:00AM	UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration (GlobeNewswire)
07:00AM	The Three Best Anti-Aging Stocks to Buy in September (InvestorPlace)
Aug-31-22 08:00AM	UNITY Biotechnology to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.18%
Aug-30-22 09:55AM	Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now (Zacks)
Aug-17-22 11:04PM	UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering (GlobeNewswire) -29.19% -37.11%
Aug-16-22 04:01PM	UNITY Biotechnology Announces Proposed Public Offering of Common Stock (GlobeNewswire) +6.20%
Aug-12-22 09:18AM	UNITY Biotech Shares More Than Double On Positive Drug Data For Diabetes Associated Vision Loss (Benzinga) +54.10%
07:05AM	UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
07:00AM	UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema (GlobeNewswire)
Aug-11-22 05:45PM	UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME (GlobeNewswire) -12.36%
Jul-12-22 04:00PM	UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting (GlobeNewswire) +5.93% +13.61%
Jun-29-22 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire)
May-26-22 08:00AM	UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors (GlobeNewswire)
May-25-22 08:00AM	UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference (GlobeNewswire)
May-10-22 04:00PM	UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -5.11%
May-05-22 08:00AM	UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases (GlobeNewswire) -6.95%
Apr-21-22 08:00AM	UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting (GlobeNewswire)
Apr-19-22 08:00AM	UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degeneration (GlobeNewswire)
Apr-12-22 08:00AM	UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema (GlobeNewswire)
Mar-17-22 12:51PM	Investors in Unity Biotechnology (NASDAQ:UBX) from three years ago are still down 88%, even after 23% gain this past week (Simply Wall St.) +6.86%
Mar-15-22 08:00AM	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates (GlobeNewswire) +6.36%
Mar-01-22 08:00AM	UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-14-22 08:00AM	UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease (GlobeNewswire) +7.10%
Feb-03-22 06:00PM	Anti-aging company Unity Biotechnology to axe half its staff, focus on eye drugs (American City Business Journals) -9.40%
04:01PM	UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs (GlobeNewswire)
Feb-02-22 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire) -7.87%
Jan-25-22 05:38PM	Arbor Wealth Management, LLC Buys Wells Fargo, Activision Blizzard Inc, Amcor PLC, Sells Altice ... (GuruFocus.com)
Jan-04-22 08:00AM	UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022 (GlobeNewswire) +6.29%
Dec-22-21 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Award (GlobeNewswire)
Dec-20-21 08:00AM	UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of -Klotho Program (GlobeNewswire) -5.00%
Nov-10-21 12:35PM	Why Did Mizuho Upgrade This Biotech Stock Focused On Age-Related Eye Diseases? (Benzinga) +23.35%
08:00AM	UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Nov-09-21 07:00AM	UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease (GlobeNewswire) +8.90%
Nov-03-21 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Awards (GlobeNewswire) -8.99%
Oct-06-21 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Awards (GlobeNewswire) -5.64%
Oct-05-21 12:15PM	Mid-Day Market Update: Crude Oil Rises 2%; UpHealth Shares Plunge (Benzinga)
07:00AM	UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease (GlobeNewswire)
Oct-04-21 01:00AM	Hedge Funds Are Piling Into Unity Biotechnology, Inc. (UBX) (Insider Monkey) -5.76%
Sep-07-21 04:00PM	UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-18-21 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Awards (GlobeNewswire)
Aug-16-21 04:03PM	UNITY Biotechnology, Inc. to Participate in the H.C. Wainwright Ophthalmology Virtual Conference (GlobeNewswire)
Aug-10-21 04:01PM	UNITY Biotechnology, Inc. Reports Second Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Jul-28-21 07:40PM	Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325 (PR Newswire)
08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Awards (GlobeNewswire)
Jul-23-21 08:00AM	UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease (GlobeNewswire)
Jul-06-21 08:59AM	Unity Biotech's UBX1325 Shows Initial Efficacy With Improved Vision, Structure In Vascular Eye Disease (Benzinga)
07:00AM	UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease (GlobeNewswire)
Jun-18-21 03:03PM	Is Unity Biotechnology, Inc. (UBX) A Good Stock To Buy? (Insider Monkey)
Jun-08-21 08:25AM	Is Unity Biotechnology, Inc. (NASDAQ:UBX) Popular Amongst Institutions? (Simply Wall St.)
Jun-02-21 08:00AM	UNITY Biotechnology Reports Granting of New Employment Inducement Awards (GlobeNewswire)
May-11-21 08:00AM	UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates (GlobeNewswire)

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sullivan Lynne Marie	CFO & Head of Corp. Dev.	Feb 04 '25	Sale	2.23	153	341	55,772	Feb 05 04:35 PM
Nguyen Alexander Hieu	CLO and Head of Ops	Feb 04 '25	Sale	2.23	164	366	24,559	Feb 05 04:33 PM
Ghosh Anirvan	Chief Executive Officer	Feb 04 '25	Sale	2.23	642	1,432	75,251	Feb 05 04:30 PM
Ghosh Anirvan	Chief Executive Officer	Nov 04 '24	Sale	1.29	432	557	75,893	Nov 06 04:10 PM
Sullivan Lynne Marie	CFO & Head of Corp. Dev.	Nov 04 '24	Sale	1.29	136	175	55,925	Nov 06 04:10 PM
Nguyen Alexander Hieu	Chief Legal Officer	Nov 04 '24	Sale	1.29	149	192	24,723	Nov 06 04:10 PM
Nguyen Alexander Hieu	Chief Legal Officer	Aug 02 '24	Sale	1.53	154	236	24,872	Aug 06 05:00 PM
Ghosh Anirvan	Chief Executive Officer	Aug 02 '24	Sale	1.53	604	924	76,325	Aug 06 05:00 PM
Sullivan Lynne Marie	CFO & Head of Corp. Dev.	Aug 02 '24	Sale	1.53	139	213	56,061	Aug 06 05:00 PM
Nguyen Alexander Hieu	Chief Legal Officer	Jun 25 '24	Sale	1.40	78	109	25,026	Jun 26 04:05 PM
Ghosh Anirvan	Chief Executive Officer	Jun 25 '24	Sale	1.40	1,214	1,700	76,929	Jun 26 04:05 PM
Sullivan Lynne Marie	CFO & Head of Corp. Dev.	Jun 25 '24	Sale	1.40	324	454	32,685	Jun 26 04:05 PM
Ghosh Anirvan	Chief Executive Officer	May 02 '24	Sale	1.55	603	935	78,143	May 03 04:05 PM

ANNX

Annexon Inc

UBX

Unity Biotechnology Inc

Upgrade your FINVIZ experience